AN OPEN-LABEL EXTENSION (OLE) PHASE 3 TRIAL TO ASSESS THE SAFETY OF INTRAVITREAL ADMINISTRATION OF AVACINCAPTAD PEGOL (COMPLEMENT C5 INHIBITOR) IN PATIENTS WITH GEOGRAPHIC ATROPHY WHO PREVIOUSLY COMPLETED PHASE 3 STUDY ISEE2008 (GATHER2)

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515185-13-00

Acronym

ISEE2009

Enrollment

126

Registered

2024-10-09

Start date

2022-12-21

Completion date

2025-04-10

Last updated

2025-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

geographic atrophy

Brief summary

AEs

Detailed description

Immunogenicity, Pharmacokinetics

Interventions

DRUGAvacincaptad pegol

DRUGFLUORESCEIN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
AEs	—

Secondary

Measure	Time frame
Immunogenicity, Pharmacokinetics	—

Countries

Austria, Belgium, Croatia, Czechia, France, Germany, Hungary, Italy, Latvia, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026